What is the recommended tapering schedule for fluvoxamine (Luvox) 200 mg?

Tapering Fluvoxamine (Luvox) 200 mg

Taper fluvoxamine gradually over several weeks to months using a slow dose reduction schedule, decreasing by approximately 25-50 mg every 1-2 weeks, monitoring closely for discontinuation symptoms, and slowing the taper if withdrawal symptoms emerge.

Key Principles for Tapering

The FDA label explicitly states that "a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" and that if intolerable symptoms occur, resuming the previously prescribed dose should be considered, followed by decreasing the dose at a more gradual rate 1. This is critical because fluvoxamine is specifically identified as one of the SSRIs with higher risk for discontinuation syndrome 2.

Recommended Tapering Schedule

Standard Taper Approach

• Starting from 200 mg daily:
  • Reduce to 150 mg for 1-2 weeks
  • Then to 100 mg for 1-2 weeks
  • Then to 50 mg for 1-2 weeks
  • Then to 25 mg for 1-2 weeks
  • Then discontinue

For Patients with Withdrawal Symptoms

• Slow the taper rate significantly if discontinuation symptoms emerge
• Consider 10-25 mg reductions every 2-4 weeks instead
• May need to pause the taper and restart when patient is ready
• The taper may take several months, which is appropriate and evidence-based 3, 4

Critical Warnings About Discontinuation

Avoid alternate-day dosing when tapering. Recent evidence demonstrates that dosing fluvoxamine every other day causes pronounced fluctuations in receptor occupancy that significantly increase withdrawal symptom risk 5. This common practice should be abandoned in favor of daily dosing at reduced amounts.

Fluvoxamine has a relatively short half-life (mean 15 hours, range 9-28 hours) 6, which contributes to its higher discontinuation syndrome risk compared to longer-acting SSRIs like fluoxetine 2.

Discontinuation Syndrome Symptoms to Monitor

Watch for these symptoms, which characteristically occur within days of dose reduction 2:

• Neurological: Dizziness, vertigo, imbalance, sensory disturbances, paresthesias
• Psychiatric: Anxiety, irritability, agitation, insomnia
• Somatic: Fatigue, lethargy, general malaise, myalgias, chills, headaches
• Gastrointestinal: Nausea, vomiting, diarrhea

Management Strategy

If Withdrawal Symptoms Occur:

1. Reinstate the previous dose that was tolerated 1
2. Stabilize for 1-2 weeks
3. Resume tapering at a slower rate (smaller decrements, longer intervals)
4. Consider extending the taper to 3-6 months total duration

Patient Education and Monitoring:

• Explain that withdrawal symptoms are not addiction but represent physiological adaptation
• Distinguish withdrawal from relapse: withdrawal symptoms typically emerge within 1-5 days of dose reduction and improve with reinstatement
• Schedule frequent follow-up (every 1-2 weeks during active taper)
• Provide reassurance that symptoms are temporary and manageable 3

Special Considerations

For patients on long-term therapy (>1 year): Even slower tapers may be needed, potentially 6-12 months total duration, following principles similar to those used for opioid tapering where 10% monthly reductions are better tolerated 7.

Hyperbolic tapering approach: Recent evidence suggests that reducing SSRI doses hyperbolically (larger reductions at higher doses, smaller reductions at lower doses) better matches the pharmacodynamic effects and may minimize withdrawal 4. This means the final reductions from 50 mg to 25 mg to discontinuation should proceed more slowly than initial reductions from 200 mg to 150 mg.

Consider liquid formulations or compounding if available to achieve smaller dose increments, particularly for the final stages of tapering below 50 mg where standard tablet strengths become limiting.

Common Pitfall to Avoid

The most significant error is following outdated guidance recommending 2-4 week tapers to minimum therapeutic doses. These rapid tapers show minimal benefit over abrupt discontinuation and are frequently not tolerated 4, 8. Current evidence supports much slower tapers extending over months and reaching doses well below minimum therapeutic levels before complete cessation.